- Home
- RECT vs SAVA Comparison
RECT vs SAVA Comparison
Compare RECT & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RECT
- SAVA
- Stock Information
- Founded
- RECT 1997
- SAVA 1998
- Country
- RECT Singapore
- SAVA United States
- Employees
- RECT N/A
- SAVA N/A
- Industry
- RECT
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- RECT
- SAVA Health Care
- Exchange
- RECT Nasdaq
- SAVA Nasdaq
- Market Cap
- RECT 66.1M
- SAVA 70.5M
- IPO Year
- RECT 2024
- SAVA N/A
- Fundamental
- Price
- RECT $4.67
- SAVA $2.01
- Analyst Decision
- RECT
- SAVA Buy
- Analyst Count
- RECT 0
- SAVA 3
- Target Price
- RECT N/A
- SAVA $54.50
- AVG Volume (30 Days)
- RECT 9.6K
- SAVA 1.3M
- Earning Date
- RECT 03-27-2025
- SAVA 05-08-2025
- Dividend Yield
- RECT N/A
- SAVA N/A
- EPS Growth
- RECT N/A
- SAVA N/A
- EPS
- RECT 0.14
- SAVA N/A
- Revenue
- RECT $33,502,767.00
- SAVA N/A
- Revenue This Year
- RECT N/A
- SAVA N/A
- Revenue Next Year
- RECT N/A
- SAVA N/A
- P/E Ratio
- RECT $33.72
- SAVA N/A
- Revenue Growth
- RECT 8.42
- SAVA N/A
- 52 Week Low
- RECT $2.70
- SAVA $1.15
- 52 Week High
- RECT $7.68
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- RECT N/A
- SAVA 55.93
- Support Level
- RECT N/A
- SAVA $2.02
- Resistance Level
- RECT N/A
- SAVA $2.22
- Average True Range (ATR)
- RECT 0.00
- SAVA 0.15
- MACD
- RECT 0.00
- SAVA 0.01
- Stochastic Oscillator
- RECT 0.00
- SAVA 42.59
About RECT Rectitude Holdings Ltd Ordinary Shares
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.